Shares surged as Novo Nordisk scored a rare win in its fight to protect its weight-loss empire. South Africa's High Court granted an interim order blocking local pharmacy group iDexis from manufacturing and selling compounded weight-loss medicines containing semaglutide, the key ingredient in Ozempic and Wegovy. NVO jumped 4.7% to $49.65 in after-hours trading, extending a rally of nearly 15% from its mid-June low of $43.19 — a bounce that matters for a stock still down roughly 68% from its December 2024 peak of $112.
The Copycat Problem Was Bigger Than Investors Realized. Novo revealed a striking number in court filings: iDexis was supplying about 84,500 compounded semaglutide units per month — more than Novo sold of Ozempic and Wegovy combined in the country.
The court rejected iDexis's argument that compounding exceptions extend to chemically similar substances, ruling only the identical active ingredient qualifies. That distinction is a legal weapon Novo can now wield in other markets where knockoffs have proliferated.
A Signal for Emerging Markets, Not a Revenue Game-Changer. The ruling sends a strong signal for patent enforcement in emerging markets, where copycat versions have spread. But context matters: South Africa is a small slice of Novo's global revenue. In Russia, local manufacturers are permitted to produce semaglutide duplicates until 2027, and in Brazil, domestic firm EMS has already launched its own version. The court order is interim — it stays in force only until South Africa's drug regulator SAHPRA concludes its investigation.
The Bigger Picture: A Revenue Decline Shareholders Can't Ignore. Novo still guides for adjusted sales and operating profit to drop 4% to 12% in 2026 at constant exchange rates.
Consensus earnings estimates sit at $3.46 per share for fiscal 2026, implying a 12.6% year-over-year decline. The oral Wegovy pill is a bright spot — it surpassed 2 million U.S. prescriptions since its January 2026 launch — but Eli Lilly's competing obesity drug continues to pressure Novo's pricing and market share.
What Comes Next. Novo reports Q2 earnings on August 5.
Wall Street's average 12-month price target of $65.56 suggests significant upside from here, but the consensus rating remains Hold, reflecting deep uncertainty over whether legal wins and a new pill can offset the pricing headwinds battering Novo's core franchise. This court order helps protect the brand — it doesn't fix the business.